Exisulind in the treatment of prostate cancer

Expert Review of Anticancer Therapy

Volumn 5, Issue 6, 2005, Pages 957-962

  Webster, W Scott ^a   Leibovich, Bradley C ^b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Exisulind; Prostate cancer; Selective apoptotic antineoplastic drugs

Indexed keywords

AMINOTRANSFERASE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; DOCETAXEL; GONADORELIN DERIVATIVE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SULINDAC SULFONE;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; BACKACHE; BILE DUCT STONE; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER THERAPY; CASTRATION; CHOLECYSTITIS; CHOLELITHIASIS; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; HEADACHE; HOT FLUSH; HUMAN; HYPERGLYCEMIA; IMPOTENCE; INDIGESTION; INFECTION; LIBIDO DISORDER; LIVER DYSFUNCTION; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; NEUTROPENIA; NONHUMAN; PANCREATITIS; PROSTATE CANCER; PROSTATE SURGERY; RESOURCE MANAGEMENT; REVIEW; SCREENING TEST; UNITED STATES;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CLINICAL TRIALS; ECONOMICS, PHARMACEUTICAL; HUMANS; MALE; PROSTATIC NEOPLASMS; SULINDAC;

EID: 29844441295     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.5.6.957     Document Type: Review

References (40)

1. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J. Clin. 55(1), 10-30 (2005).
2. Bostwick DG, Burke HB, Djakiew D et al. Human prostate cancer risk factors. Cancer 101(Suppl. 10), 2371-2490 (2004).
3. Cooperberg MR, Broering JM, Litwin MS et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J. Urol. 171(4), 1393-1401 (2004).
4. Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N. Engl. J. Med. 352(19), 1977-1984 (2005).
5. Holmberg L, Bill-Axelson A, Helgesen F et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. [see comment]. N. Engl. J. Med. 347(11), 781-789 (2002).
6. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. [see comment]. Cancer 95 (2), 281-286 (2002).
7. D'Amico AV, Moull J, Carroll PR et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J. Clin. Oncol. 21(11), 2163-2172(2003).
8. Bott SR, Birtle AJ, Taylor CJ et al. Prostate cancer management: (1) an update on localised disease. Postgrad Med. J. 79(936), 575-580 (2003).
9. Ward JF, Blute ML, Slezak J et al. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J. Urol. 170(5), 1872-1876 (2003).
10. Roach M III, DeSilvio M, Lawton C et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group [see comment]. J. Clin. Oncol. 21(10), 1904-1911 (2003).
11. Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study), a Phase III randomised trial. Lancet 360(9327), 103-106 (2002).
12. Pilepich MV, Winter K, Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of Phase III RTOG 85-31. Int. J. Radiat. Oncol. Biol. Phys. 61(5), 1285-1290 (2005).
13. D'Amico AV, Manola J, Loffredo M et al. 6-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292(7), 821-827 (2004).
14. Smith MR. Osteoporosis and obesity in men receiving hormone therapy for prostate cancer. J. Urol. 172(5 Pt 2), S52-S57 (2004).
15. Sato N, Akakura K, Isaka S et al. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Urology 64(2), 341-345 (2004).
16. Amling CL, Bergstralh EJ, Blute ML et al. Defining prostate specific antigen progression after radical prostatectomy. what is the most appropriate cut point? J. Urol. 165(4), 1146-1151 (2001).
17. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int. J. Radiat. Oncol. Biol. Phys. 37(5), 1035-1041 (1997).
18. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J. Urol. 162(2), 293-306 (1999).
19. Zhou P, Chen MH, McLeod D et al. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J. Clin. Oncol. 23(28), 6992-6998 (2005).
20. Ward JF, Moull JW. Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. Curr. Opin. Urol. 15(3), 187-195 (2005).
21. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351(15), 1513-1520 (2004).
22. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502-1512 (2004).
23. Moore CN, George DJ. Update in the management of patients with hormone-refractory prostate cancer. Curr. Opin. Urol. 15(3), 157-162 (2005).
24. Soh JW, Mao Y, Kim MG et al. Cyclic GMP mediates apoprosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1. Clin. Cancer Res. 6(10), 4136-4141 (2000).
25. Soh JW, Mao Y, Liu L et al. Protein kinase G activates the JNK1 pathway via phosphorylation of MEKK. J. Biol. Chem. 276(19), 16406-16410 (2001).
26. Thompson WJ, Piazza GA, Li H et al. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated β-catenin. Cancer Res. 60(13), 3338-3342 (2000).
27. Basu S, Kolesnick R. Stress signals for apoptosis: ceramide and c-Jun kinase. Oncogene 17(25), 3277-3285 (1998).
28. Lim JT, Piazza GA, Pamukcu R et al. Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells. Clin. Cancer Res. 9(13), 4972-4982 (2003).
29. Lim JT, Piazza GA, Han EK et al. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem. Pharmacol. 58(7), 1097-1107 (1999).
30. Goluboff ET, Shabsigh A, Saidi JA et al. Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology 53(2), 440-445 (1999).
31. Narayanan BA, Narayanan NK, Pittman B et al. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin. Cancer Res. 10(22), 7727-7737 (2004).
32. Witta SE, Gustafson DL, Pierson AS et al. A Phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors. Clin. Cancer Res. 10(21), 7229-7237 (2004).
33. Stoner GD, Budd GT, Ganapathi R et al. Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv. Exper. Med. Biol. 470, 45-53 (1999).
34. van Stolk R, Stoner G, Hayton WL et al. Phase I trial of exisulind (sulindac sulfone FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin. Cancer Res. 6(1), 78-89 (2000).
35. Goluboff ET. Exisulind, a selective apoptotic antineoplastic drug. Expert opin. Investig. Drugs 10(10), 1875-1882 (2001).
36. Jones SF, Kuhn JG, Greco FA et al. A Phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer. Clin. Lung Cancer 6(6), 361-366 (2005).
37. Pusztai L, Zhen JH, Arun B et al. Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. J. Clin. Oncol. 21(18), 3454-3461 (2003).
38. Goluboff ET, Prager D, Rukstalis D et al. Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy. J. Urol. 166(3), 882-886 (2001).
39. Ryan CW, Stadler WM, Vogelzang NJ. A Phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer. Br. J. Urol. Int. 95, 963-968 (2005).
40. Blute ML, Bergstralh, EJ, Iocca A et al. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J. Urol. 165(1), 119-125 (2001).